EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference
EyePoint Pharmaceuticals (NASDAQ: EYPT), a company focused on developing therapeutics for serious retinal diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Jay S. Duker, M.D., the company's President and CEO, will deliver a presentation on January 14, 2025 at 2:15 p.m. PT/5:15 p.m. ET in San Francisco. Investors and interested parties can access the presentation webcast and replay through the Investors section of EyePoint's website.
EyePoint Pharmaceuticals (NASDAQ: EYPT), un'azienda focalizzata sullo sviluppo di terapie per gravi malattie retiniche, ha annunciato la sua partecipazione al 43° Annual J.P. Morgan Healthcare Conference. Jay S. Duker, M.D., presidente e amministratore delegato dell'azienda, terrà una presentazione il 14 gennaio 2025 alle 14:15 PT/17:15 ET a San Francisco. Gli investitori e le parti interessate possono accedere alla trasmissione in diretta e alla registrazione della presentazione attraverso la sezione Investitori del sito web di EyePoint.
EyePoint Pharmaceuticals (NASDAQ: EYPT), una empresa centrada en desarrollar terapias para enfermedades retinianas graves, ha anunciado su participación en la 43ª Conferencia Anual de Salud J.P. Morgan. Jay S. Duker, M.D., presidente y director ejecutivo de la compañía, ofrecerá una presentación el 14 de enero de 2025 a las 2:15 p.m. PT/5:15 p.m. ET en San Francisco. Los inversores y partes interesadas pueden acceder a la transmisión en vivo y la repetición de la presentación a través de la sección de Inversores en el sitio web de EyePoint.
EyePoint Pharmaceuticals (NASDAQ: EYPT) 는 심각한 망막 질환 치료제를 개발하는 데 집중하는 회사로, 제43회 연례 J.P. 모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다. Jay S. Duker, M.D., 회사의 회장 겸 CEO가 2025년 1월 14일 오후 2시 15분 PT / 오후 5시 15분 ET에 샌프란시스코에서 발표를 진행할 예정입니다. 투자자 및 관심 있는 당사자는 EyePoint 웹사이트의 투자자 섹션을 통해 발표의 웹캐스트 및 재생을 이용할 수 있습니다.
EyePoint Pharmaceuticals (NASDAQ: EYPT), une entreprise axée sur le développement de thérapies pour des maladies rétiniennes graves, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare. Jay S. Duker, M.D., le président et PDG de l'entreprise, effectuera une présentation le 14 janvier 2025 à 14h15 PT/17h15 ET à San Francisco. Les investisseurs et les parties intéressées peuvent accéder au webinaire et à la rediffusion de la présentation via la section Investisseurs du site Web d'EyePoint.
EyePoint Pharmaceuticals (NASDAQ: EYPT), ein Unternehmen, das sich auf die Entwicklung von Therapeutika für schwere Netzhauterkrankungen konzentriert, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare Conference angekündigt. Jay S. Duker, M.D., der Präsident und CEO des Unternehmens, wird am 14. Januar 2025 um 14:15 PT/17:15 ET in San Francisco eine Präsentation halten. Investoren und Interessierte können über den Bereich Investoren auf der Website von EyePoint auf den Webcast und die Wiederholung der Präsentation zugreifen.
- None.
- None.
WATERTOWN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 2:15 p.m. PT/5:15 p.m. ET.
A webcast and subsequent archived replay of the presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com.
About EyePoint Pharmaceuticals
EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU™ (f/k/a EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. DURAVYU is presently in Phase 3 global, pivotal clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States, and in a Phase 2 clinical trial in diabetic macular edema (DME). EyePoint expects full topline data from the Phase 2 clinical trial in DME in Q1 2025 and topline data from both Phase 3 pivotal trials in wet AMD in 2026.
Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Investors:
Christina Tartaglia
Precision AQ
Direct: 212-698-8700
christina.tartaglia@sternir.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
FAQ
When is EyePoint Pharmaceuticals (EYPT) presenting at the J.P. Morgan Healthcare Conference 2025?
How can investors watch EyePoint's (EYPT) J.P. Morgan Healthcare Conference presentation?
Who will represent EyePoint Pharmaceuticals (EYPT) at the 2025 J.P. Morgan Healthcare Conference?
Which annual J.P. Morgan Healthcare Conference will EyePoint (EYPT) be presenting at?
